Your session is about to expire
← Back to Search
SNS-101 + Cemiplimab for Cancer
Study Summary
This trial tests a new antibody drug to treat advanced solid tumors, to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had treatment for another cancer within the last 2 years, except for early-stage cancer treated with the aim of cure.I experienced severe side effects from previous immunotherapy.I haven't used specific therapies in the last 2 weeks.I have no ongoing major side effects from previous cancer treatments.I am not pregnant or breastfeeding.My cancer is advanced, cannot be surgically removed, or has spread.My cancer can be measured by tests.I have brain metastasis or leptomeningeal disease, with or without symptoms.I agree to give samples of my tumor before and during treatment.My organs are working well.I agree to use effective birth control during and for 6 months after the study, and not to donate eggs or sperm.I am fully active or can carry out light work.I have tried and cannot tolerate the usual treatment for my advanced cancer, or I am not eligible for it.
- Group 1: Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion
- Group 2: Part B - SNS-101 in combination with cemiplimab and Dose Expansion
- Group 3: Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it possible to enroll in this medical research project at the present time?
"Affirmative. According to clinicaltrials.gov, this medical experiment has been open for recruitment since June 1st 2023 and was recently revised on May 18th of the same year. The research is requiring 129 patients across two sites."
How many participants are currently participating in this experiment?
"Affirmative. Documentation listed on clinicaltrials.gov confirms that the study, which was announced in June of 2023, is currently actively recruiting participants from two sites with a target enrollment of 129 individuals."
What is the overarching aim of this medical experiment?
"According to Sensei Biotherapeutics, Inc., the primary outcome that will be evaluated over the span of a year is Adverse Events - Part A & B. In addition, further investigations into secondary outcomes such as Adverse Events - Part C (incidence and severity of any adverse reactions), SNS-101's pharmacokinetics in terms of maximum concentration and serum terminal half life are planned."
Share this study with friends
Copy Link
Messenger